AZILSARTAN MEDOXOMIL (azilsartan medoxomil) by Hetero is angiotensin-converting enzymes (ace, kinase ii). Approved for hypertension in adults, to lower blood pressure.
Drug data last refreshed 22h ago
angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan…
Worked on AZILSARTAN MEDOXOMIL at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)
International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension